Pulsenmore Ltd. Form 6-K — Oct 13, 2026

Form 6-KFiled Oct 13, 2026, 7:28 AM ET0001493152-26-046729Original filing

Pulsenmore Ltd. (Nasdaq/TASE: PLSM) appointed med-tech veteran David Woods as Chief Commercial Officer on October 13, 2026, alongside an expansion of its U.S. commercial team. Woods brings over 25 years of medtech leadership experience, most recently as CCO at Creo Medical and previously as President and CEO of PENTAX Medical Americas.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.